WO2001074392A1 - Preparations sous forme de microspheres contenant un antagoniste de recepteur de neurokinine 1 - Google Patents

Preparations sous forme de microspheres contenant un antagoniste de recepteur de neurokinine 1 Download PDF

Info

Publication number
WO2001074392A1
WO2001074392A1 PCT/JP2001/002530 JP0102530W WO0174392A1 WO 2001074392 A1 WO2001074392 A1 WO 2001074392A1 JP 0102530 W JP0102530 W JP 0102530W WO 0174392 A1 WO0174392 A1 WO 0174392A1
Authority
WO
WIPO (PCT)
Prior art keywords
vomiting
receptor antagonist
neurokinin
preparations containing
administration
Prior art date
Application number
PCT/JP2001/002530
Other languages
English (en)
Japanese (ja)
Inventor
Takehiko Suzuki
Masahiko Tanimoto
Hirokazu Yamakita
Masahito Okamoto
Yuzo Matsuoka
Original Assignee
Tanabe Seiyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co., Ltd. filed Critical Tanabe Seiyaku Co., Ltd.
Priority to AU2001244572A priority Critical patent/AU2001244572A1/en
Publication of WO2001074392A1 publication Critical patent/WO2001074392A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des préparations sous forme de microsphères qui contiennent un antagoniste de récepteur de neurokinine 1 et un polymère pratiquement non hydro-soluble, biocompatible et biodégradable, et qui sont très utiles en médecine clinique, grâce à leur capacité d'inhiber efficacement les vomissements aigus, les vomissements tardifs et les vomissements anticipés provoqués par l'administration de substances vomitives (produits chimiothérapeutiques contre le cancer, analgésiques opioïdes, etc.), par la radiothérapie et analogue, et d'empêcher les effets secondaires des vomissements dans la chimiothérapie du cancer et la radiothérapie. Les vomissements peuvent être efficacement inhibés au moyen d'une seule administration parentérale de l'antagoniste de récepteur de neurokinine 1 durant la période correspondante, comparée à l'administration par intraveineuse d'une solution aqueuse de l'antagoniste de récepteur de neurokinine 1 une fois par jour. En outre, l'antagoniste de récepteur de neurokinine 1 est contenu dans une quantité égale, voire inférieure à la quantité requise pour inhiber les vomissements sur une longue période par une seule administration par intraveineuse de la solution aqueuse de l'antagoniste de récepteur de neurokinine 1 une fois par jour.
PCT/JP2001/002530 2000-03-30 2001-03-28 Preparations sous forme de microspheres contenant un antagoniste de recepteur de neurokinine 1 WO2001074392A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001244572A AU2001244572A1 (en) 2000-03-30 2001-03-28 Microsphere preparations containing neurokinin 1 receptor antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-93540 2000-03-30
JP2000093540 2000-03-30

Publications (1)

Publication Number Publication Date
WO2001074392A1 true WO2001074392A1 (fr) 2001-10-11

Family

ID=18608713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/002530 WO2001074392A1 (fr) 2000-03-30 2001-03-28 Preparations sous forme de microspheres contenant un antagoniste de recepteur de neurokinine 1

Country Status (2)

Country Link
AU (1) AU2001244572A1 (fr)
WO (1) WO2001074392A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074896A1 (fr) * 2004-02-10 2005-08-18 Takeda Pharmaceutical Company Limited Preparation pour liberation soutenue

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554763A (en) * 1992-09-30 1996-09-10 Sanofi 1-azoniabicyclo[2.2.1] heptanes and pharmaceutical compositions in which they are present
JPH10203966A (ja) * 1996-11-21 1998-08-04 Takeda Chem Ind Ltd 徐放性マイクロカプセルおよびその製造法
JPH11171787A (ja) * 1997-12-12 1999-06-29 Teikoku Hormone Mfg Co Ltd ドラスタチン１０誘導体を含有するマイクロスフエア製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554763A (en) * 1992-09-30 1996-09-10 Sanofi 1-azoniabicyclo[2.2.1] heptanes and pharmaceutical compositions in which they are present
JPH10203966A (ja) * 1996-11-21 1998-08-04 Takeda Chem Ind Ltd 徐放性マイクロカプセルおよびその製造法
JPH11171787A (ja) * 1997-12-12 1999-06-29 Teikoku Hormone Mfg Co Ltd ドラスタチン１０誘導体を含有するマイクロスフエア製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.A. RUDD ET AL.: "The action of the NK1 tachykinin receptor antagonist, CP99, 994, in antagonizing the acute and delayed emesisi induced by cisplatin in the ferret", BRITISH JOURNAL OF PHARMACOLOGY, vol. 119, 1996, pages 931 - 936, XP002942021 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074896A1 (fr) * 2004-02-10 2005-08-18 Takeda Pharmaceutical Company Limited Preparation pour liberation soutenue
US7662408B2 (en) 2004-02-10 2010-02-16 Takeda Pharmaceutical Company Limited Sustained-release preparations

Also Published As

Publication number Publication date
AU2001244572A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
NO20020924L (no) Injiserbare buprenorfinmikropartikkelpreparater og deres anvendelse
WO2001043749A3 (fr) Implant pharmacologique contenant des composants a liberation immediate et a liberation prolongee et procede d'administration
AU2002235155A1 (en) Crystallization inhibition of drugs in transdermal drug delivery systems
AU2573499A (en) Implantable drug infusion device having an improved valve
EP0301856A3 (en) Delivery system
KR950702409A (ko) 방출 조절 모르핀 제제(controlled release morphine preparation)
MXPA02007762A (es) Sistema de suministro de farmaco pulsativos temporalizados.
TR200102002T2 (tr) Ağız yoluyla verildikten sonra gliklazid'in uzun sürede salınmasını sağlayan matris tablet.
EP1003373A4 (fr) Compositions et methodes permettant d'attenuer la depression respiratoire et les effets secondaires des composes opioides mu
WO2001087263A3 (fr) Dispositifs d'administration pour le traitement d'affection vasculaire
EP1244471A4 (fr) Composition liquide d'un copolymere bloc biodegradable destinee a un systeme d'administration de medicaments et procede de fabrication correspondant
CA2336815A1 (fr) Composition et forme galenique pharmaceutique servant a administrer un medicament au colon au moyen de polysaccharides
NZ320545A (en) Injectable quinolone formulations
IL136512A0 (en) Intravenous infusion administration set
Horan et al. The physical dependence liability of butorphanol: a comparative study with morphine
WO2001032181A3 (fr) Compositions pharmaceutiques contenant un medicament antibiotique de fluoroquinolone et une gomme xanthan
WO2001074392A1 (fr) Preparations sous forme de microspheres contenant un antagoniste de recepteur de neurokinine 1
ES2196180T3 (es) Sistema de suministro de liberacion sostenida y analgesicos de narcoticos y antagonistas de accion prolongada.
FR2796287B1 (fr) Dispositif d'administration de medicament
ZA200004468B (en) Metered dose infusion pump and method.
AU2020201307A1 (en) Abuse-Resistant Controlled-Release Opioid Dosage Form
CA2264745A1 (fr) Procede inhibant la biosynthese de l'eif5a
AU3278800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
HK1046847B (zh) 包括撲熱息痛和丁螺環酮的止痛藥物組合
CA2400578A1 (fr) Compositions a liberation regulee contenant des agonistes et antagonistes de l'opioide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP